Product Description
Piclidenoson's mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in deregulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. (Sourced from: https://www.canfite.com/category/Piclidenoson)
Mechanisms of Action: ADORA3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ewopharma AG
Company Location: Europe
Company CEO:
Additional Commercial Interests: Can-Fite BioPharma
Clinical Description
Countries in Clinic: Greece, Poland
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Can-Fite BioPharma announced they will present P3 Psoriasis results in 2Q26 for Piclidenoson
- Clinical Outcomes Reported - Can-Fite BioPharma presented P3 Psoriasis results on 2024-01-29 for Piclidenoson
Highest Development Phases
Phase 3: Psoriasis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06643260 |
CF101-302PS | P3 |
Not yet recruiting |
Psoriasis |
2027-12-01 |
53% |
2024-10-17 |
|
2024-519919-34-00 |
CF101-302PS | P3 |
Not yet recruiting |
Psoriasis |
2028-01-31 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/26/2025 |
News Article |
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction |
|
12/23/2025 |
News Article |
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change |
|
12/16/2025 |
News Article |
Can-Fite Provides Update on Clinical and Financial Status |
|
11/26/2025 |
News Article |
Can-Fite's Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference |
|
04/16/2024 |
PubMed |
Cryo-EM structures of adenosine receptor A3AR bound to selective agonists. |
|
01/26/2024 |
PubMed |
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1). |
|
06/01/2023 |
PubMed |
New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults. |